Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Clinical Trials
3625
1517 active
Approvals
156
Total approvals
Agencies
5
Regulatory bodies
Founded
N/A
Unknown
8
0.2%
Completed
1772
48.9%
Enrolling By Invitation
2
0.1%
Not yet recruiting
35
1.0%
No Longer Available
3
0.1%
Terminated
132
3.6%
Recruiting
148
4.1%
Approved For Marketing
9
0.3%
Available
3
0.1%
Withdrawn
28
0.8%
Active, not recruiting
1480
40.8%
- Novo Nordisk reported that CagriSema produced an estimated average weight loss of 12.4% in a late-stage trial in patients with diabetes. - A 1 mg dose of CagriSema was superior to 5 mg tirzepatide for weight loss, which achieved 9.1% in the same head-to-head study. - CagriSema also demonstrated non-inferior blood sugar reduction versus tirzepatide in patients with diabetes, and a separate late-stage obesity study showed 21% weight loss versus placebo. - Novo Nordisk is targeting an early 2026 launch for the CagriSema combination, with an FDA decision on its weight management application expected in the fourth quarter.
- Novo Nordisk told its Capital Markets Day in London it aims to launch more than five blockbuster drugs by 2030 and generate over 150 billion Danish kroner in pipeline sales by 2035. - The company detailed a staged obesity injectable rollout: CagriSema launch targeted for early next year, standalone cagrilintide and high-dose CagriSema in 2028, then zenagamtide. - Novo aims to reach more than 60 million patients globally by 2030 and scale manufacturing tenfold to supply 15 million patients with oral obesity therapies by decade's end. - Semaglutide, the active ingredient in Ozempic and Wegovy, has lost patent exclusivity in Canada, India, Brazil and Turkey this year, with Europe and the U.S. running into the early 2030s.
- More than 90 lawsuits have been filed in New Jersey state court against Novo Nordisk on behalf of patients who developed NAION after taking Ozempic or Wegovy. - The European Medicines Agency concluded in June 2025 that NAION is a very rare side effect of semaglutide, while the FDA continues investigating without requiring a US label warning. - Denmark has paid more than $1.5 million to 27 patients who developed vision loss after Ozempic or Wegovy, with 38 additional cases still under review. - Evidence on causality remains mixed, with studies reporting risk increases from roughly two-fold to nearly eight-fold while a Novo Nordisk-supported study found no increased risk.
- Eli Lilly has opened a Phase 2 trial called FORAY testing the oral FGFR3 inhibitor vepugratinib in adults with early bladder and upper tract urothelial cancers. - The study targets low grade, intermediate risk tumors carrying FGFR3 alterations, a setting where targeted treatment options are currently limited. - FORAY is an open-label, randomized parallel-group interventional trial that is listed as not yet recruiting, with each patient followed for up to five years. - The trial entry was first submitted and last updated on September 15, 2026, and no primary or final completion dates have been posted.
- The Trump administration said all 50 state Medicaid programs have agreed to participate in the GENEROUS international reference-pricing model, which launched in January as a five-year voluntary program. - CMS calculates a most-favored-nation price from manufacturer-reported data in eight countries, using the second-lowest net international price adjusted for purchasing power parity. - A White House analysis estimated a Medicaid MFN framework could save about $64.3 billion over 10 years, though KFF says savings depend on participation and confidential pricing data. - Documents obtained by Public Citizen show Pfizer agreed to share part of net increased foreign revenue with HHS from January 2026 through January 2029 under its MFN contract.
- The FDA granted full approval to imlunestrant (Inluriyo) plus abemaciclib (Verzenio) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one prior endocrine therapy line. - In the Phase 3 EMBER-3 trial, the all-oral combination doubled median progression-free survival to 11.1 months versus 5.5 months with imlunestrant alone (HR=0.53; 95% CI, 0.35-0.80). - Most adverse events with the combination were Grade 1 or 2, with permanent discontinuation of imlunestrant in 1% of patients and of abemaciclib in 3.4% of patients. - The approval is the second for Inluriyo in under a year, following its September 2025 monotherapy clearance, while the adjuvant EMBER-4 trial of more than 8,000 patients reports initial results in 2027.
- Novo Nordisk has halted two additional heart-failure trials of its experimental cardiovascular drug ziltivekimab, ending them ahead of schedule. - An independent data monitoring committee found a low likelihood the two studies would differ from a prior late-stage trial in which ziltivekimab failed to reduce major adverse cardiovascular events. - One ziltivekimab study continues in patients recovering from a heart attack, with results expected in the first half of 2027. - The decision narrows Novo Nordisk's cardiovascular pipeline and increases its reliance on the obesity and diabetes franchise, where it competes with Eli Lilly.
- Health Secretary Yvette Cooper told The i Paper the government will look at making dementia drugs available on the NHS after changes to NICE cost-effectiveness guidance. - Lecanemab, sold as Leqembi, and donanemab were licensed in the UK in 2024 but NICE declined to recommend either for NHS use on cost grounds. - NICE has paused its evaluation of lecanemab while the NHS and manufacturer Eisai hold commercial talks, with similar discussions under way with Eli Lilly.
- The EMA's CHMP recommended marketing authorization for FREHEMGO (denecimig), a factor VIIIa mimetic bispecific antibody for routine prophylaxis in hemophilia A. - The positive opinion covers adults and children with hemophilia A, with or without factor VIII inhibitors, using a prefilled pen dosed weekly, biweekly or monthly. - CHMP's decision rested on the phase 3 FRONTIER program, where mean annualized bleeding rates stayed below one and many patients had zero treated bleeds. - Novo Nordisk expects first European launches in Q4 2026 with broader EU rollout in early 2027, while a US Biologics License Application filed in September 2025 remains under review.
- Novo Nordisk has filed Wegovy Pill (semaglutide) and Eli Lilly has filed Foundayo (orforglipron) for South Korean marketing authorization with the Ministry of Food and Drug Safety. - Both oral candidates launched in the US at $149 per month at the starting dose, roughly 85% below the $1,000 US starting price of injectable Wegovy and Mounjaro. - Hanmi Pharmaceutical targets October approval for its injectable EPPE, which cut weight 9.75% at 40 weeks in a 448-patient South Korean Phase 3 trial.
